Skip to main content

Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells.

Publication ,  Journal Article
Mir, SS; Richter, BW; Duckett, CS
Published in: Blood
December 15, 2000

CD30 is a member of the tumor necrosis factor (TNF) receptor superfamily that is expressed on activated lymphocytes, as well as on neoplastic cells of Hodgkin disease (HD) and anaplastic large cell lymphoma (ALCL). A number of reports have shown that, depending on cellular context, CD30 signaling can exert a variety of effects, ranging from cell death to cellular proliferation. In the present study this disparity was examined, using a number of ALCL- and HD-derived cell lines. Activation of CD30 led to the induction of apoptotic death of ALCL cells, along with the selective reduction of TNF receptor-associated factor 2 and impairment in the ability of these cells to activate the pro-survival transcription factor nuclear factor kappa B (NF-kappa B). In contrast, HD cells, which constitutively express NF-kappa B, were not susceptible to CD30-induced apoptosis but could be sensitized following ectopic overexpression of a superdominant I kappa B. These studies suggest that NF-kappa B plays a determining role in the sensitivity or resistance of lymphoma cells to CD30-induced apoptosis, which may have important consequences in the clinical treatment of CD30-positive neoplasia. (Blood. 2000;96:4307-4312)

Duke Scholars

Published In

Blood

ISSN

0006-4971

Publication Date

December 15, 2000

Volume

96

Issue

13

Start / End Page

4307 / 4312

Location

United States

Related Subject Headings

  • Tumor Cells, Cultured
  • TNF Receptor-Associated Factor 2
  • Signal Transduction
  • Recombinant Fusion Proteins
  • Proteins
  • Neoplasm Proteins
  • NF-kappa B
  • NF-KappaB Inhibitor alpha
  • Lymphoma, Large B-Cell, Diffuse
  • Ki-1 Antigen
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mir, S. S., Richter, B. W., & Duckett, C. S. (2000). Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood, 96(13), 4307–4312.
Mir, S. S., B. W. Richter, and C. S. Duckett. “Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells.Blood 96, no. 13 (December 15, 2000): 4307–12.
Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000 Dec 15;96(13):4307–12.
Mir, S. S., et al. “Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells.Blood, vol. 96, no. 13, Dec. 2000, pp. 4307–12.
Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000 Dec 15;96(13):4307–4312.

Published In

Blood

ISSN

0006-4971

Publication Date

December 15, 2000

Volume

96

Issue

13

Start / End Page

4307 / 4312

Location

United States

Related Subject Headings

  • Tumor Cells, Cultured
  • TNF Receptor-Associated Factor 2
  • Signal Transduction
  • Recombinant Fusion Proteins
  • Proteins
  • Neoplasm Proteins
  • NF-kappa B
  • NF-KappaB Inhibitor alpha
  • Lymphoma, Large B-Cell, Diffuse
  • Ki-1 Antigen